menu
    • menu
    [{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Promontory Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Promontory Therapeutics

    Menu

    Promontory Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promontory Completes Enrollment of PT112 in Castration-Resistant Prostate Cancer

                            Details : PT-112 (imifoplatin) is the first small-molecule conjugate of pyrophosphate in clinical development in oncology. It is being evaluated for metastatic castration-resistant prostate cancer.

                            Brand Name : PT-112

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 08, 2024

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demons...

                            Details : PT-112 (imifoplatin) is the first small-molecule conjugate of pyrophosphate in clinical development in oncology and inhibitor of ribosomal biogenesis (RiBi) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor...

                            Brand Name : PT-112

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 05, 2023

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to Fr...

                            Details : PT-112 is the first small-molecule conjugate of pyrophosphate in clinical development in oncology and inhibitor of ribosomal biogenesis (RiBi) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironm...

                            Brand Name : PT-112

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 20, 2023

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promontory Therapeutics to Present Clinical Trial for PT-112 in Prostate Cancer at the ASCO 2023 Genitourinary...

                            Details : PT-112 is the first small-molecule conjugate of pyrophosphate that promotes immunogenic cell death, through the release of damage associated molecular patterns that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tu...

                            Brand Name : PT-112

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 02, 2023

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promontory Therapeutics Presents Safety and Efficacy Data of PT-112 in Combination with PD-L1 Inhibition in Tr...

                            Details : PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs).

                            Brand Name : PT-112

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : Imifoplatin,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promontory Therapeutics to Present Research on PT-112 in Prostate Cancer at the 34th EORTC-NCI-AACR Symposium

                            Details : PT-112 is the first small-molecule conjugate of pyrophosphate, and possesses a unique pleiotropic MOA that promotes ICD, through the release of DAMPs that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microe...

                            Brand Name : PT-112

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Promontory Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promontory Therapeutics Announces Peer Reviewed Publication of First-in-Human Clinical Trial of PT-112 in The ...

                            Details : PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD) through the release of damage associated molecular patterns (DAMPs) that bind to ...

                            Brand Name : PT-112

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2022

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth